FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947945944> ?p ?o ?g. }

• W2947945944 abstract "Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, including the spectrum, timing, and outcomes, of ICI-induced neurologic toxicities are not well characterized.We performed disproportionality analysis using Vigibase, the World Health Organization pharmacovigilance database, comparing neurologic adverse event (AE) reporting in patients receiving ICIs vs. the full database. Neurologic AEs were classified by group queries using Medical Dictionary for Regulatory Activities, between database inception to September 28, 2018. Associations between ICIs and neurologic AEs were assessed using reporting odds ratios (ROR) and information component (IC). IC compares observed and expected values to find associations between drugs and AEs using disproportionate Bayesian reporting; IC025 (lower end of the IC 95% credibility interval) > 0 is considered statistically significant.Among the full database, 18,518,994 AEs were reported, including 48,653 with ICIs. ICIs were associated with higher incidence of myasthenia gravis (0.47% of ICI reports vs. 0.04% of the full database, ROR 16.5 [95% CI 14.5-18.9]; IC025 3.31), encephalitis (0.51% vs. 0.05%, ROR 10.4 [95% CI 9.2-11.8]; IC025 3.15), peripheral neuropathy (1.16% vs. 0.67%, IC025 0.68), and meningitis (0.15% vs. 0.06%, ROR 3.1 [95% CI 2.5-3.9]; IC025 1.01). Myasthenia gravis and encephalitis were associated with anti-PD-1 whereas other neurologic AEs were associated with anti-CTLA-4. Myasthenia gravis was characterized by high fatality rates (~ 20%), early onset (median 29 days), and frequent concurrent myocarditis and myositis; whereas other neurologic AEs had lower fatality rates (6-12%), later onset (median 61-80 days), and were non-overlapping.ICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations." @default.
• W2947945944 created "2019-06-07" @default.
• W2947945944 creator A5019401898 @default.
• W2947945944 creator A5025067315 @default.
• W2947945944 creator A5030606411 @default.
• W2947945944 creator A5035350944 @default.
• W2947945944 creator A5041066886 @default.
• W2947945944 creator A5050098540 @default.
• W2947945944 creator A5063177685 @default.
• W2947945944 creator A5086895898 @default.
• W2947945944 creator A5089113899 @default.
• W2947945944 date "2019-05-22" @default.
• W2947945944 modified "2023-10-10" @default.
• W2947945944 title "Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study" @default.
• W2947945944 cites W2005366883 @default.
• W2947945944 cites W2015487160 @default.
• W2947945944 cites W2124319844 @default.
• W2947945944 cites W2152641996 @default.
• W2947945944 cites W2158299492 @default.
• W2947945944 cites W2167186282 @default.
• W2947945944 cites W2338423971 @default.
• W2947945944 cites W2532352313 @default.
• W2947945944 cites W2547133566 @default.
• W2947945944 cites W2569887568 @default.
• W2947945944 cites W2612010935 @default.
• W2947945944 cites W2779221466 @default.
• W2947945944 cites W2783137027 @default.
• W2947945944 cites W2791483720 @default.
• W2947945944 cites W2793167197 @default.
• W2947945944 cites W2801142990 @default.
• W2947945944 cites W2801620857 @default.
• W2947945944 cites W2808959710 @default.
• W2947945944 cites W2889081896 @default.
• W2947945944 cites W2891486030 @default.
• W2947945944 cites W2895125473 @default.
• W2947945944 cites W2896438236 @default.
• W2947945944 cites W2896676995 @default.
• W2947945944 cites W2897539371 @default.
• W2947945944 cites W2900596992 @default.
• W2947945944 cites W2901191795 @default.
• W2947945944 cites W4252639669 @default.
• W2947945944 doi "https://doi.org/10.1186/s40425-019-0617-x" @default.
• W2947945944 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6530194" @default.
• W2947945944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31118078" @default.
• W2947945944 hasPublicationYear "2019" @default.
• W2947945944 type Work @default.
• W2947945944 sameAs 2947945944 @default.
• W2947945944 citedByCount "199" @default.
• W2947945944 countsByYear W29479459442019 @default.
• W2947945944 countsByYear W29479459442020 @default.
• W2947945944 countsByYear W29479459442021 @default.
• W2947945944 countsByYear W29479459442022 @default.
• W2947945944 countsByYear W29479459442023 @default.
• W2947945944 crossrefType "journal-article" @default.
• W2947945944 hasAuthorship W2947945944A5019401898 @default.
• W2947945944 hasAuthorship W2947945944A5025067315 @default.
• W2947945944 hasAuthorship W2947945944A5030606411 @default.
• W2947945944 hasAuthorship W2947945944A5035350944 @default.
• W2947945944 hasAuthorship W2947945944A5041066886 @default.
• W2947945944 hasAuthorship W2947945944A5050098540 @default.
• W2947945944 hasAuthorship W2947945944A5063177685 @default.
• W2947945944 hasAuthorship W2947945944A5086895898 @default.
• W2947945944 hasAuthorship W2947945944A5089113899 @default.
• W2947945944 hasBestOaLocation W29479459441 @default.
• W2947945944 hasConcept C107130276 @default.
• W2947945944 hasConcept C120665830 @default.
• W2947945944 hasConcept C121332964 @default.
• W2947945944 hasConcept C126322002 @default.
• W2947945944 hasConcept C156957248 @default.
• W2947945944 hasConcept C187316915 @default.
• W2947945944 hasConcept C197934379 @default.
• W2947945944 hasConcept C199475168 @default.
• W2947945944 hasConcept C203014093 @default.
• W2947945944 hasConcept C2522874641 @default.
• W2947945944 hasConcept C2778105408 @default.
• W2947945944 hasConcept C2781460105 @default.
• W2947945944 hasConcept C41008148 @default.
• W2947945944 hasConcept C57658597 @default.
• W2947945944 hasConcept C61511704 @default.
• W2947945944 hasConcept C71924100 @default.
• W2947945944 hasConcept C77088390 @default.
• W2947945944 hasConcept C83455156 @default.
• W2947945944 hasConceptScore W2947945944C107130276 @default.
• W2947945944 hasConceptScore W2947945944C120665830 @default.
• W2947945944 hasConceptScore W2947945944C121332964 @default.
• W2947945944 hasConceptScore W2947945944C126322002 @default.
• W2947945944 hasConceptScore W2947945944C156957248 @default.
• W2947945944 hasConceptScore W2947945944C187316915 @default.
• W2947945944 hasConceptScore W2947945944C197934379 @default.
• W2947945944 hasConceptScore W2947945944C199475168 @default.
• W2947945944 hasConceptScore W2947945944C203014093 @default.
• W2947945944 hasConceptScore W2947945944C2522874641 @default.
• W2947945944 hasConceptScore W2947945944C2778105408 @default.
• W2947945944 hasConceptScore W2947945944C2781460105 @default.
• W2947945944 hasConceptScore W2947945944C41008148 @default.
• W2947945944 hasConceptScore W2947945944C57658597 @default.
• W2947945944 hasConceptScore W2947945944C61511704 @default.
• W2947945944 hasConceptScore W2947945944C71924100 @default.
• W2947945944 hasConceptScore W2947945944C77088390 @default.
• W2947945944 hasConceptScore W2947945944C83455156 @default.

• next